AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
MediciNova to Present at H.C. Wainwright Global Investment Conference
ByAinvest
Wednesday, Sep 3, 2025 7:05 am ET1min read
MediciNova, a biopharmaceutical company, will present a corporate overview at the H.C. Wainwright 27th Annual Global Investment Conference. Yuichi Iwaki, President and CEO, and David Crean, Chief Business Officer, will present on September 5, 2025. The presentation will be available on-demand and can be accessed on the MediciNova website. Drs. Iwaki and Crean will be available for one-on-one meetings throughout the conference.
MediciNova, Inc., a biopharmaceutical company listed on the NASDAQ Global Market (NASDAQ: MNOV) and the Standard Market of the Tokyo Stock Exchange (Code Number: 4875), will present a corporate overview at the H.C. Wainwright 27th Annual Global Investment Conference. The presentation will be delivered by Yuichi Iwaki, MD., Ph.D., President and CEO, and David H. Crean, Ph.D., Chief Business Officer, on September 5, 2025 [1].The conference, scheduled from September 8 to 10, 2025, at the Lotte New York Palace Hotel, will feature a live webcast of the presentation available on-demand beginning at 7:00am ET on September 5, 2025. The webcast can be accessed via the investor relations section of the MediciNova website, with a replay archived for approximately 90 days [1].
MediciNova, Inc. is a clinical-stage biopharmaceutical company developing a broad late-stage pipeline of novel small molecule therapies for inflammatory, fibrotic, and neurodegenerative diseases. Its lead asset, MN-166 (ibudilast), is currently in Phase 3 for amyotrophic lateral sclerosis (ALS) and degenerative cervical myelopathy (DCM), and is Phase 3-ready for progressive multiple sclerosis (MS). MN-166 (ibudilast) is also being evaluated in Phase 2 trials for Long COVID and substance dependence. Another key compound, MN-001 (tipelukast), was evaluated in a Phase 2 trial for idiopathic pulmonary fibrosis (IPF), with a second Phase 2 trial ongoing for non-alcoholic fatty liver disease (NAFLD) [1].
Drs. Iwaki and Crean will be available for one-on-one meetings throughout the conference. Interested parties can register for the event and request meetings via the H.C. Wainwright conference website [1].
References:
[1] https://www.marketscreener.com/news/medicinova-to-present-at-the-h-c-wainwright-27th-annual-global-investment-conference-ce7d59dad180fe23
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet